US-Listed Shares of Cosciens Biopharma Fall 50.5% Premarket as Drug for Growth Hormone Deficiency Fails to Meet Main Goal of Late-Stage Study
科希恩斯生物製藥在盤前交易中下跌50.5%,因生長激素缺乏症的藥物在晚期研究中未達到主要目標
US-Listed Shares of Cosciens Biopharma Fall 50.5% Premarket as Drug for Growth Hormone Deficiency Fails to Meet Main Goal of Late-Stage Study
科希恩斯生物製藥在盤前交易中下跌50.5%,因生長激素缺乏症的藥物在晚期研究中未達到主要目標
譯文內容由第三人軟體翻譯。